Plain-English translation of NCT07044336 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new drug called (also called AZD8205) to see if it helps people with advanced endometrial cancer live longer and healthier lives. The medication is being compared to standard chemotherapy drugs that doctors currently use. About 700 people will be randomly assigned to receive either the new medication or one of two standard chemotherapy options.
Endometrial cancer that has spread or come back after previous chemotherapy and immunotherapy is very difficult to treat. This medication works in a new way, and researchers want to see if it might be more effective than the current standard chemotherapy options available to these patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two treatment groups. One group will receive the new medication as an IV infusion once every three weeks, while the other group will receive standard chemotherapy (either once every three weeks or on days 1, 8, and 15 of each 28-day cycle). Throughout the trial, you will have regular visits to receive treatment and have your health monitored with scans and blood tests to see how well the treatment is working and how it affects your quality of life.
AI-generated summary from trial data · Aug 4, 2026 · Not medical advice
United States